European Patent Office

T 0663/02 du 17.03.2011

Identifiant européen de la jurisprudence
ECLI:EP:BA:2011:T066302.20110317
Date de la décision
17 mars 2011
Numéro de l'affaire
T 0663/02
Requête en révision de
-
Numéro de la demande
96944505.5
Classe de la CIB
G01R 33/563
Langue de la procédure
Anglais
Distribution
Distribuées aux présidents et aux membres des chambres de recours (B)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
-
Titre de la demande
Method for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
Nom du demandeur
Prince, Martin, R.
Nom de l'opposant
Koninklijke Philips Electronics N.V.
Chambre
3.4.01
Sommaire

I. The fact that an intravenous injection of a magnetic resonance contrast agent can be delegated by a physician to a qualified paramedical professional indicates that such an injection may be considered as representing a minor routine intervention which does not imply a substantial health risk when carried out with the required care and skill. Such acts would be ruled out from the scope of the application of the exclusion clause pursuant to Article 53(c) EPC following the narrow understanding advocated by the EBA (G 0001/04 and 0001/07) (Reasons, 3.2.4).

II. A possible way of assessing health risks is to use a risk matrix permitting to combine the levels of likelihood and health impact of a complication of a medical act with regard to a large number of patients, so as to obtain statistical health risk scores which may be used to decide what action should be taken. Such a risk assessment supports the view that an intravenous injection of a magnetic resonance contrast agent represents a minor routine intervention involving no substantial health risks when carried out with the required care and skill (Reasons, 3.2.5).

Dispositions juridiques pertinentes
European Patent Convention Art 53(c)
Mots-clés
-
Exergue
-

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is maintained as granted.